Nayak Jasmir G, White Christopher W, Nates Wayne, Sharda Rajan, Horne David, Kaler Kam, Lytwyn Mark, Grocott Hilary P, Freed Darren H, McGregor Thomas
Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB;
Section of Cardiac Surgery, Department of Surgery, University of Manitoba, Winnipeg, MB;
Can Urol Assoc J. 2013 Sep-Oct;7(9-10):E640-4. doi: 10.5489/cuaj.400.
Left ventricular assist device (LVAD) therapy is an established treatment option for select patients with advanced heart failure. Advances in technology and patient management have resulted in improved post-implant outcomes. Consequently, more patients with LVADs are presenting for evaluation and care of non-cardiac surgical disease. However, there is a paucity of literature regarding the optimal perioperative and surgical management of such patients. We present the case of a 71-year-old male with a HeartMate II (Thoratec Corporation, Pleasanton, CA) LVAD, who underwent a laparoscopic left nephroureterectomy for an upper urinary tract transitional cell carcinoma. His perioperative course was uneventful due to the multidisciplinary efforts of cardiac surgery, cardiac anesthesia, nephrology and urology. To our knowledge, this is the first reported case of a laparoscopic nephroureterectomy in a patient with a HeartMate II LVAD.
左心室辅助装置(LVAD)治疗是特定晚期心力衰竭患者的既定治疗选择。技术和患者管理方面的进步已使植入后的治疗效果得到改善。因此,越来越多植入LVAD的患者前来评估和治疗非心脏外科疾病。然而,关于此类患者最佳围手术期和手术管理的文献却很匮乏。我们报告一例71岁男性患者,其植入了HeartMate II(Thoratec公司,加利福尼亚州普莱森顿)左心室辅助装置,因上尿路移行细胞癌接受了腹腔镜下左肾输尿管切除术。由于心脏外科、心脏麻醉、肾脏病学和泌尿外科学的多学科协作,其围手术期过程顺利。据我们所知,这是首例关于植入HeartMate II左心室辅助装置患者行腹腔镜肾输尿管切除术的报道病例。